2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2014
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2014, 22: 175-183. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEnd-stage liver diseaseCost-effectiveness analysisF3-F4Liver diseaseChronic hepatitis C genotype 1 patientsHepatitis C genotype 1 patientsItalian National Health System perspectiveNational Health System perspectiveResponse-guided therapyGenotype 1 patientsMETAVIR fibrosis stageHealth system perspectiveQuality-adjusted life yearsPatient selection strategiesCost-effectiveness ratioG1 patientsNaive patientsTriple therapyOnly patientsAdvanced fibrosisFuture regimensMore regimensTreatment optionsFibrosis stage